SS-31 (Elamipretide): The Mitochondrial Peptide, Explained

SS-31 has a better story than most peptides in the longevity world. It was designed by academic researchers, it targets a well-defined structure inside your cells, and it’s now an FDA-approved drug.

That last part is exactly why it’s worth being precise. Approved for what, based on what evidence, and how far does that stretch? Here’s the honest version, with corrections to some details we got wrong in an earlier version of this post.

What SS-31 Is

SS-31 is a small synthetic peptide made of four amino acids. It belongs to the Szeto-Schiller (SS) peptide family, named after its developers, Hazel Szeto and Peter W. Schiller, who described the work on these compounds in Pharmaceutical Research.

The names can be confusing, so here’s the short version:

• SS-31 is the research name.
• Elamipretide is the generic drug name. (Earlier codes included MTP-131 and Bendavia.)
• Forzinity is the brand name of the approved product from Stealth BioTherapeutics.

How It Works: Cardiolipin

Most peptides people talk about work by binding a receptor on the outside of a cell. SS-31 is different. It goes inside cells and concentrates at the inner membrane of the mitochondria, the structures that produce most of your cellular energy.

There, it binds a fat called cardiolipin. In a review of the compound’s development, Szeto (2014) explains why that matters. Cardiolipin helps shape the folds inside mitochondria and organize the protein complexes that make energy. When it’s damaged, those complexes work less efficiently. SS-31 binds cardiolipin, protects that structure, and helps keep a key protein, cytochrome c, doing its normal energy-carrying job.

That’s an elegant mechanism. Cardiolipin problems show up in many conditions linked to energy failure. But a good mechanism isn’t the same as a proven benefit, and that’s where the evidence gets more mixed.

The Approval: Barth Syndrome

In September 2025, FDA granted accelerated approval to Forzinity as the first treatment for Barth syndrome, in patients weighing at least 30 kg.

Barth syndrome is a rare, serious genetic disease caused by mutations in the TAFAZZIN gene, which disrupt cardiolipin. In other words, it’s the condition where SS-31’s mechanism fits most directly.

Two details are worth knowing:

It’s accelerated approval. FDA based it on improved strength in the muscle that straightens the knee, a measure it considers reasonably likely to predict real benefit. The manufacturer has to run a confirmatory trial to show that it does.

The supporting data are small. In the long-term open-label extension of the TAZPOWER trial, Thompson et al. (2024) followed ten patients, eight of whom reached the final visit. Elamipretide was well tolerated, with injection-site reactions the most common side effect, and patients improved on walking tests. That’s meaningful for a rare disease with no other approved treatment. It’s also ten people.

What “Accelerated Approval” Actually Means

The phrase sounds like a stamp of extra confidence. It’s closer to the opposite: a deliberate trade of certainty for speed in serious diseases with few options.

FDA explains that its accelerated approval pathway, created in 1992, allows drugs for serious conditions with an unmet medical need to be approved based on a surrogate or intermediate endpoint. That’s a measurement thought to predict real clinical benefit, like how patients survive, feel or function, without directly proving it. For Forzinity, that measure was knee extensor strength.

The company then has to run confirmatory trials. If those trials verify the benefit, the requirement ends. If they fail to verify it, FDA says the approval may be withdrawn or the labeled use changed.

So the honest reading of SS-31’s approval is: for one rare disease, there’s enough promise to give patients access now, and the full proof is still coming. That’s a good outcome for people with Barth syndrome. It’s not evidence for anything else.

Where It Didn’t Work

The story isn’t all wins. In primary mitochondrial myopathy, a broader group of mitochondrial muscle diseases, the Phase 3 MMPOWER-3 trial by Karaa et al. (2023) did not meet its primary endpoints. Elamipretide didn’t significantly improve walking distance or fatigue compared with placebo.

That matters. It shows that even a compound with a strong mechanism doesn’t automatically help every condition that involves mitochondria.

The Longevity Leap

Here’s the claim you’ll see everywhere: cardiolipin damage is part of aging, SS-31 protects cardiolipin, so SS-31 slows aging.

Each step sounds reasonable. Put together, it’s a hypothesis, not a result. Animal studies have been encouraging, as Szeto’s review describes. But there are no human trials showing that SS-31 slows aging, improves energy, or boosts performance in healthy people. The only approved use is a rare genetic disease.

If you see confident week-by-week timelines for what SS-31 will do for your energy, recovery or skin, ask where the data came from. We used to include one. We’ve removed it, because we couldn’t back it up.

What Evidence Would Change the Picture

It’s worth being specific about what would move SS-31 from hypothesis to recommendation for broader use. Not to dismiss it, but because knowing what good evidence looks like makes it easier to spot when it arrives.

A successful confirmatory trial in Barth syndrome. This would turn the accelerated approval into a confirmed benefit in the condition where the mechanism fits best.

Positive randomized trials in other conditions. Ideally placebo-controlled, with outcomes patients care about, like walking distance, fatigue or heart function, rather than lab markers alone.

Trials in healthy or aging adults. For longevity claims, you’d want randomized trials measuring something meaningful, like physical function or fitness over a long period, along with long-term safety data.

Independent replication. Results from groups without a financial stake would add confidence, as they would for any compound.

Until some of that exists, the accurate summary for healthy people is “interesting, unproven.” That’s not cynicism. It’s what the data says right now.

Red Flags in SS-31 Marketing

If you see these, be skeptical:

• Claims that SS-31 is “FDA-approved” without saying it’s approved only for Barth syndrome
• Week-by-week timelines for energy, skin or performance with no source
• Animal results presented as if they happened in people
• “Research use only” labels on products clearly marketed for personal use
• No independent testing of what’s in the vial

Legal and Quality Reality

Elamipretide is a prescription drug approved for one rare condition. Products sold online as “SS-31” for research aren’t the approved product, and you have no way to verify what’s in the vial. FDA has made clear that labeling a product “for research only” doesn’t stop it from being an unapproved drug when it’s marketed for human use.

If mitochondrial health is a genuine concern for you, especially if you have symptoms, that’s a conversation with a physician, ideally one who knows mitochondrial medicine.

If You’re Tracking Mitochondrial Health Anyway

You don’t need SS-31 to care about your mitochondria. The levers with the best evidence are training, sleep and metabolic health. And they’re all trackable.

Aerobic fitness. Track it with a repeatable test, like a fixed-distance run or a cycling benchmark, or a VO2 max estimate from your wearable. Watch the trend, not individual readings.

Resting heart rate and HRV. Rolling averages reflect your overall recovery and fitness. Our guide to HRV and recovery explains how to read them.

Sleep. The foundation for everything else. Our sleep stack guide covers what actually moves it.

Metabolic markers. Fasting glucose, HbA1c and lipids, tested under consistent conditions. See our blood panel guide.

How you feel. A simple daily energy rating is surprisingly useful once you have a few months of it.

Pinnacle Pulse lets you log all of these on one timeline, so you can see whether anything you change, from training to sleep to a prescribed treatment, actually shows up in the data.

So Where Does SS-31 Stand?

It’s one of the more scientifically serious compounds in the longevity conversation. It has a clear mechanism, an FDA approval for a rare disease, and a failed Phase 3 in a broader one. What it doesn’t have is evidence for the uses most people online are excited about.

Keep an eye on the confirmatory Barth syndrome trial. That will tell us more than any forum post. And for how peptides are regulated more broadly, see What Are Peptides?.

This article is for educational purposes only and is not medical advice. Forzinity (elamipretide) is a prescription medicine approved only for Barth syndrome. Don’t use any compound without the guidance of a qualified clinician.

FAQ

Is SS-31 the same as elamipretide?

Yes. SS-31 is the research name and elamipretide is the generic drug name. Forzinity is the brand name of the FDA-approved product, made by Stealth BioTherapeutics.

What is Forzinity approved for?

FDA granted Forzinity accelerated approval in September 2025 as the first treatment for Barth syndrome, a rare mitochondrial disease, in patients weighing at least 30 kg. It is not approved for aging, energy or performance.

Does SS-31 slow aging in humans?

That hasn't been shown. The mechanism is relevant to aging and animal results are interesting, but there are no human trials showing it slows aging or extends healthspan in healthy people.